Archive for December, 2019

Yeast isn't just found in bread it can also be found in everybodys genitals. Everyone has it, but it only causes an issue when it becomes out of balance with your bodys natural pH.

Vaginal candidiasis, or yeast infection, is a fungal infection that causes irritation, discharge and intense itchiness of the vagina and the vulva. This is NOT considered an STI. Theyre super common, and affect three-fourths of vagina owners at least once in their lifetime. Many people experience at least two episodes. There are over-the-counter medications that can treat them; however, you should always go to your doctor first, and if you experience recurrent ones, then you should talk to your doctor about different treatments and treatment plans.

For those with a penis, the yeast infection is referred to as candidal (or candida) balanitis. It affects the head of the penis mostly, but can also affect foreskin and the shaft depending on the intensity. For symptoms, you should usually look for burning or itching around the head (especially after having penetrative sex), redness, swelling, small bumps that may contain pus and pain during urination or sex. If you have a foreskin, you may also have difficulty cleaning or moving the foreskin. Unlike with vaginal yeast infections, penile yeast infections are usually acquired through sexual intercourse, but are generally easily treated. Additionally, you may acquire a yeast infection through skin problems or taking certain kinds of antibiotics (which can cause imbalance for the bodys natural genital pH).

You might have a yeast infection in your vagina if you notice these symptoms: Itching and irritation, burning during sex or urination, redness and swelling of the vulva, pain and soreness, a vaginal rash, thick, white, cottage cheese-like discharge or very watery discharge. All peoples discharge is different however. Always ask your doctor about sudden changes in discharge.

Yeast infections are caused by an imbalance in the natural bacteria and strains of yeast inside the vagina. It becomes an infection when the yeast becomes more present than the bacteria that normally keeps it in check. This imbalance can be caused by a number of things, including antibiotic use, which causes an imbalance in the natural vaginal flora, pregnancy, uncontrolled diabetes, an impaired immune system or taking oral contraceptives or hormone therapy that increase estrogen levels.

Remember as well that yeast and bacteria flourish in a damp, warm environment. So, if you fit into any of the above criteria, you can take steps to prevent yeast infections from occurring. Mayo Clinic and Healthline both recommend wearing slightly looser fitting underwear that has a cotton panel in the crotch, as well as avoiding super tight-fitting tights or leggings and being sure to change out of wet or damp workout clothing or swimsuits as soon as youre done. Additionally, refrain from taking extremely hot showers or baths, because the hot, wet environment can exacerbate the issue. You should also refrain from douching. The vagina is self-cleaning, and does not require help in its job. Douching the vagina can only cause worse issues.

You should definitely avoid having sex if you believe you may have a yeast infection of any kind. Bacteria thrives in moist environments, and genitals are the perfect breeding spot. Having sex with a partner may unbalance your partners pH, and you will be exposing them to the risk of infection as well. Its best to just wait it out. Mild infections can have symptoms disappear after only a few days of treatment, while more moderate to severe infections may last anywhere from one to three weeks.

If you think you may have a yeast infection, the best first step is to see a professional. The kind of doctor associated with genital health is a gynecologist for vaginas, and urologists specialize in penile care. Many options are available as well for those who wish to treat at home, such as antifungal treatments (here is a link for over-the-counter treatment of the penis). However, it should be acknowledged that you should check with your general practitioner to address any risks and seek medical attention if symptoms persist for more than the amount of time recommended on the package.

Do you have a question about sex, sexuality, or relationships? You can ask us to find you accurate and reliable information from experts by tweeting @SEATUTK, direct messaging @Sexweekut on Facebook or submitting a question to our anonymous Google form.

Columns and letters of The Daily Beacon are the views of the individual and do not necessarily reflect the views of the Beacon or the Beacon's editorial staff.

See the rest here:
Let's Talk About It: Yeast Infections - UT Daily Beacon

NewsReal LifeEva Echo came out as transgender to wife Pippa two years ago despite fearing it could mean their relationship was over

Tuesday, 3rd December 2019, 5:40 pm

Eva Echo, 39, and her wife Pippa Ng, 29, talk about how Eva's coming out as trans made their relationship stronger, as well as the mental health struggles she faced on her journey to self acceptance.

It was obvious what the customer in Eva's tattoo shop was doing. The smirk on his face after he took a sly snap of her on his phone said it all. "He was clearly sending snaps to his friends, probably telling them, Have a look at this freak," she said.

She knew she stood out. "At that time, adopting an androgynous look and wearing make-up was a sort of comfortable middle ground for me. But I couldnt even say the word transgender, let alone admit it to myself."

The truth was that being called by the male name she was given at birth, and the male body she was born into, had been the root of years of torment. The multiple suicide attempts five major ones that led to hospitalisations. An eating disorder. The self-loathing. The denial.

"I'd always tried to imitate my friends and be 'one of the lads'," she said. "But I wasn't and my mental health problems were because I had no solid sense of identity, of who I really was as a person."

Then at the age of 37, there in the shop was a reminder of everything she'd been afraid of social rejection, ridicule, discrimination and abuse. Transphobia. But the way forward suddenly became clearer.

This guy really made me wake up and question who I was. I thought, how do people see me, when I dont even know how I see me? If people are already laughing at me, then fuck it, why not go the whole hog?"

Coming out

Eva opened up to her best friend Christine, who was "super supportive", which gave her the courage to tell Pippa, who she'd met at a gig six years ago, and married eight months later.

But Pippa had dated only men. I knew I needed to tell Pippa, but I was a nervous wreck. She already accepted me for who I was and the way I looked. So that made it easier to come out to her. But I know people who come out to their partners and they say it's okay, then some time later it all falls apart. I thought, what if it's really not okay for her?"

Eva swigged back a few glugs of vodka and took a deep breath. There was no going back once the words were said. "I told her everything. She wasn't even surprised. She just sort of shrugged and said, I know'.

It was huge for me. Shes the most important thing in my life. She wasnt angry. Id built things up to be so horrific that it was the ultimate turning point for me. To be accepted for exactly who you are makes you feel really truly loved. Pippa is very protective over me and gets upset if anyone stares at me."

Pippa says she always had a strong feeling Eva was struggling with her gender. "It's not like Eva was this big, burly man who dropped a bombshell about wearing my clothes behind closed doors. I'd never gone for butch men."

And while Pippa never labelled herself, she said she identifies with being pansexual, that is knowing she is attracted to people regardless of their sex or gender identity. "I always dated men and have never dated a woman. But I was aware that was because I'd never met a woman who I felt really attracted to.

"For me love is love, as they say. I really like the phrase 'Love is hearts not parts'. I was just relieved that Eva could now put a name to what was making her so unhappy. And I look and dress a bit 'different' myself. So I can identify with that. Both of us feel sure that we don't want children, so thankfully that's not an issue for us."

Journey to acceptance

And so almost immediately, Eva, from near Birmingham, took steps to begin her transition. But after going to her GP and being referred to a gender identity clinic (GIC) , she was devastated to be told the waiting list had jumped to two-and-a-half years. Like many trans people struggling to access timely help, she considered buying potentially-dangerous hormones online.

"The wait was just for an initial appointment, it would have been longer for me to have anything done. I feel like I knew from the age of four, but it can take trans people like myself years and years to get to a place of realising you're in the wrong body. Then you take this big leap and you expect the help to be there. But every year that passed was another year of not being me."

Fearful of suffering further mental health problems, she sought a diagnosis and hormone therapy from private firm Gender Care, where the waiting list was just three months. She also recently underwent facial feminisation surgery with surgeon Christopher Inglefield, who featured in ITV documentary Transformation Street.

Eva said she isn't on speaking terms with her parents, who have struggled to accept the changes. "I'm Chinese, and while I think culture has played a role, I know of more open minded Chinese families. I understand that they came over from Hong Kong back in the day when there was more open racism and they have struggled themselves with feeling like they fit in."

Pippa's family meanwhile have accepted Eva with open arms. "My dad was brilliant straight away, my mum was too, it just took her a bit longer to remember to refer to Eva as she, or her 'daughter-in-law'.

"At a family do I my granddad was great. He called Eva by her original male name and I explained she was called Eva now. He just hugged and kissed her like he would any woman. If someone of that generation can embrace it, that gives us hope."

You can read Eva's blog where she shares about her transition here.

Do you have a story about relationships to share? Email claudia.tanner@inews.co.uk

There are just seven GICs in England London being the main one, as well as Sheffield, Leeds, Newcastle, Daventry, Nottingham and Exeter to serve a UK trans population estimated to be as large as 660,000.

Record demand for help from NHS gender identity clinics has seen waiting times reach more than two years, research has shown.

Providers of such services say they are not adequately funded by NHS England, according to an investigation by Health Service Journal.

There are no official waiting time statistics, but four of the six providers in England shared their data with the publication which discovered providers are reporting average waiting times of more than two years.

Tavistock and Portman Foundation Trust, the countrys largest provider of transgender services, said back in August when the report came out that its waiting list for a first appointment, at 5,717, is at an all-time high.

One expert clinician says his service is four times over subscribed in terms of what its funded to deliver.

NHS England said its budget for gender identity services increased to 38m in 2019-20, compared to 34m the previous year. However, it acknowledged the problems and said it will be piloting new delivery models.

Campaigners say transgender people are being put at greater risk of suicide and self-harm because of long waits.

A spokesperson for the Tavistock said that in addition to an "an unprecedented increase" in the number of referrals to its service, they are also having to deal with a high staff turnover and patients cancelling appointments. A statement read: "We are aware that the waiting time for a first appointment at GICS is currently growing and are doing all we can to address this."

Original post:
Relationship diaries: 'Love is about hearts not parts' says wife on accepting her partner as trans - inews

Market Research Hub (MRH) has actively discoursed a new study titled Global Bone Marrow Transplant Rejection Treatment Market Professional Survey Report 2019, added to its vast online repository. The main motive of this assessment is to present clear insights about the growth factor experienced across the Bone Marrow Transplant Rejection Treatment Market during the forecast period. Readers can access vital information associated to prime market facets such as market size, market share, market drivers, future trends, challenges, opportunities and sales channels. Furthermore, the availability of competitive developments including leading market players make the report a rich data source for investors and new entrants.

Get Sample Copy @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2560597

The global Bone Marrow Transplant Rejection Treatment market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.

This report focuses on Bone Marrow Transplant Rejection Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bone Marrow Transplant Rejection Treatment market size by analyzing historical data and future prospect.

Regionally, this report categorizes the production, apparent consumption, export and import of Bone Marrow Transplant Rejection Treatment in North America, Europe, China, Japan, Southeast Asia and India.

For each manufacturer covered, this report analyzes their Bone Marrow Transplant Rejection Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:Bellicum Pharmaceuticals, Inc.Bio-Cancer Treatment International LimitedBiogen IncBoryung Pharmaceutical Co., Ltd.Bristol-Myers Squibb CompanyCantex Pharmaceuticals, Inc.Capricor Therapeutics, Inc.Cell Source, Inc.Cell2B S.A.CellECT Bio, Inc.Cleveland BioLabs, Inc.Compugen Ltd.Cynata Therapeutics LimitedCytodyn Inc.Dompe Farmaceutici S.p.A.Dr. Falk Pharma GmbHEscape Therapeutics, Inc.F. Hoffmann-La Roche Ltd.Fate Therapeutics, Inc.Generon (Shanghai) Corporation Ltd.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAzathioprineAdrenocorticotropic HormoneCyclophosphamideCyclosporine AOthers

Segment by ApplicationHospitalClinicOthers

Browse Complete Report @ https://www.marketresearchhub.com/report/global-bone-marrow-transplant-rejection-treatment-market-professional-survey-report-2019-report.html

Table of Contents

Executive Summary1 Industry Overview of Bone Marrow Transplant Rejection Treatment1.1 Definition of Bone Marrow Transplant Rejection Treatment1.2 Bone Marrow Transplant Rejection Treatment Segment by Type1.2.1 Global Bone Marrow Transplant Rejection Treatment Production Growth Rate Comparison by Types (2014-2025)1.2.2 Azathioprine1.2.3 Adrenocorticotropic Hormone1.2.4 Cyclophosphamide1.2.5 Cyclosporine A1.2.6 Others1.3 Bone Marrow Transplant Rejection Treatment Segment by Applications1.3.1 Global Bone Marrow Transplant Rejection Treatment Consumption Comparison by Applications (2014-2025)1.3.2 Hospital1.3.3 Clinic1.3.4 Others1.4 Global Bone Marrow Transplant Rejection Treatment Overall Market1.4.1 Global Bone Marrow Transplant Rejection Treatment Revenue (2014-2025)1.4.2 Global Bone Marrow Transplant Rejection Treatment Production (2014-2025)1.4.3 North America Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.4 Europe Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.5 China Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.6 Japan Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.7 Southeast Asia Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.8 India Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis2.1 Raw Material and Suppliers2.2 Manufacturing Cost Structure Analysis of Bone Marrow Transplant Rejection Treatment2.3 Manufacturing Process Analysis of Bone Marrow Transplant Rejection Treatment2.4 Industry Chain Structure of Bone Marrow Transplant Rejection Treatment

3 Development and Manufacturing Plants Analysis of Bone Marrow Transplant Rejection Treatment3.1 Capacity and Commercial Production Date3.2 Global Bone Marrow Transplant Rejection Treatment Manufacturing Plants Distribution3.3 Major Manufacturers Technology Source and Market Position of Bone Marrow Transplant Rejection Treatment3.4 Recent Development and Expansion Plans4 Key Figures of Major Manufacturers4.1 Bone Marrow Transplant Rejection Treatment Production and Capacity Analysis4.2 Bone Marrow Transplant Rejection Treatment Revenue Analysis4.3 Bone Marrow Transplant Rejection Treatment Price Analysis4.4 Market Concentration Degree

Enquire More about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2560597

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceutical Market and analysis. MRHs expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: [emailprotected]

Website: http://www.marketresearchhub.com/

Read Industry News at: https://www.industrynewsanalysis.com/

See the article here:
Bone Marrow Transplant Rejection Treatment Market Status, Types and Applications and Forecast to 2025 - News Description

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See original here:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire

Dec. 2, 2019 10:30 UTC

CAMBRIDGE, Mass. & SEATTLE--(BUSINESS WIRE)-- Cyrus Biotechnology, Inc., and the Broad Institute of MIT and Harvard have embarked on a scientific collaboration to optimize CRISPR for use in developing novel human therapeutics.

CRISPR allows for the highly specific and rapid modification of DNA in a genome, which can dramatically accelerate the drug discovery process.

Feng Zhang will be the principal investigator for the Broad for the collaboration. He is also an investigator of the Howard Hughes Medical Institute (HHMI).

Together, researchers from Cyrus and Broad will work together to mitigate the possibility of the body mounting an immune response against CRISPR. The teams are committed to making the results of their collaboration broadly available for research to help ensure that therapeutic development bringing this technology to the clinic has the best chance of success, while also considering important ethical and safety concerns. The teams have also committed to publishing their results in peer reviewed journals and to make this work freely available to the non-profit and academic scientific community.

Issi Rozen, chief business officer at the Broad Institute, said, Broad researchers and their collaborators have pioneered the development and sharing of new genome editing tools, such as CRISPR-Cas9, which are revolutionizing and accelerating nearly every aspect of disease research and drug discovery around the world. With this collaboration, scientists will continue to improve the technology towards new tools and therapeutics, important to benefiting patients in the long term.

Cyrus CEO Dr. Lucas Nivn added, We have validated our computational deimmunization platform in a variety of systems, and now seek to apply it where it can make a major impact. Given the extensive therapeutic possibilities of CRISPR systems, and the leading position the Broad Institute and Dr. Zhang hold, we are very excited to work in partnership with them to make these molecules more amenable for use in humans with maximal efficacy and minimal side effects.

Cyrus provides commercial and partnered access to Rosetta, which is the worlds leading protein modeling and design software platform. Rosetta has been used to direct the computational design of multiple biologic molecules that have advanced to both pre-clinical and clinical development. Among these are drugs being developed by companies including PVP Biologics, Tocagen, Lyell and others.

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Bakers laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

Home

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005078/en/

See the original post:
Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology -...

Global CRISPR in Agriculture Market valued approximately USD XX million in 2016 is anticipated tgrow with a healthy growth rate of more than XX% over the forecast period 2017-2025. Increasing demand in drug discovery, late pregnancies leading tbirth disorders, synthetic genes leading the way; aging genetic disorders and investment in path breaking research technology are the drivers for CRISPR Market. Drug discovery technology market plays a dominant role in boosting the CRISPR market. Genome editing has been revolutionized with the discovery of the CRISPR-CAS9 system from streptococcus pyogenes.

Request a Sample Copy of this[emailprotected]https://www.orbisresearch.com/contacts/request-sample/2129000

The objective of the study is tdefine market sizes of different segments & countries in recent years and tforecast the values tthe coming eight years. The report is designed tincorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report alscaters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall alsincorporate available opportunities in micrmarkets for stakeholders tinvest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Crop Type:Staple CropsFruits & VegetablesOrnamentalsOthers

By Regions:North AmericaU.S.CanadaEuropeUKGermanyAsia PacificChinaIndiaJapanLatin AmericaBrazilMexicoRest of the World

To make an enquiry on[emailprotected]https://www.orbisresearch.com/contacts/enquiry-before-buying/2129000

Furthermore, years considered for the study are as follows:Historical year 2015Base year 2016Forecast period 2017 t2025

Some of the key manufacturers involved in the market are:

DuPont, Cibus, Monsanto, Bayer AG. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Browse full[emailprotected]https://www.orbisresearch.com/reports/index/global-crispr-in-agriculture-market-forecasts-2017-2025

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas 75204, U.S.A.

Phone No:+1 (214) 884-6817; +912064101019

Email ID:[emailprotected]

Read the original:
CRISPR in Agriculture Market 2019 by Services, Application, Key Players, Size, Trends and Forecast 2025 - Downey Magazine

Cancer | One of the most common disease in the world

In what may prove as a breakthrough in the treatment of leukaemia and other blood diseases, scientists at UCLA have discovered a protein produced by a gene known as MLLT3 and its connection to the multiplication of human blood stem cells.

The discovery which was published in a study is very much significant as cancers such as leukaemia can be effectively treated using blood stem cells, also known as Hematopoietic stem cells (HSCs), produced outside the human body and could serve as an alternative to existing treatment options such as bone marrow transplants.

Self-renewal is the process by which stem cells divide to create more cells. The study focused on a specific type of the kind: Hematopoietic stem cells (HSCs) which are present within the bone marrow where along with self-renewal, they also produce different types of blood cells such as red and white by transforming into them.

Placing HSCs in laboratory dishes after their removal from the bone marrow causes then to lose their ability to self-renew, and they either transform into other blood types or perish. It is this process that the scientists studied. Through a series of steps, the researchers studied the genes that shutdown as the cells lost their capacity to self-renew.

They discovered that the HSCs' ability to self-renew corresponded with the expression of a gene called MLLT3. They also found that MLLT3 generated a protein that instructed HSCs to retain their capacity to self-renew. As the cells divide, the protein works along with other regulatory proteins to keep vital components of the HSCs' functioning.

Employing a viral vector the researchers tried to ascertain if maintaining the MLLT3 protein levels in lab dishes would help improve the self-renewing abilities of HSCs. A viral vector is a specially designed virus that transfers genetic information to the nucleus of a cell without giving rise to a disease. Using the vector, the scientists introduced an active MLLT3 gene into HSCs. They found that there was nearly a twelvefold multiplication of working HSCs in lab dishes.

"If we think about the amount of blood stem cells needed to treat a patient, that's a significant number," said Dr. Hanna Mikkola, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and senior author of the study, to the UCLA Newsroom.

The UCLA scientists observed that the use of 'small molecules' organic compounds that help in the multiplication of human HSCs, improved self-renewal in general. However, the cells were unable to maintain stable MLLT3 levels and did not perform well when implanted into mice.

"Our method, which exposes blood stem cells to the small molecules and also inserts an active MLLT3 gene, created blood stem cells that integrated well into mouse bone marrow, efficiently produced all blood cell types and maintained their self-renewing ability," said Vincenzo Calvanese, a UCLA project scientist and the study's co-corresponding author, to the UCLA Newsroom.

The team noted that the self-renewal of HSCs caused by MLLT3 was at a safe rate. This means that they did not acquire potent characteristics such as mutation or excessive multiplication, or the production aberrant cells that can cause leukaemia.

Determining which proteins and constituents within the DNA of the HSCs affect the activation and deactivation of MLLT3 is the next step for the team. Also, understanding the regulation of the process using components in the lab dishes is another step. The information gathered may help find ways in which MLLT3 could be switched on and off without employing a viral vector.

Read more:
Protein that can help treatment of leukemia identified, UCLA scientists upbeat - International Business Times, Singapore Edition

2 December 2019

Stem cell therapies may become redundant in repairing cardiac function after a heart attack, suggests a new study in mice.

It showed how stem cell treatments can heal hearts by triggering an immune response which can be achieved by using a chemical instead.

'This work is paradigm-shifting because it demonstrates a mechanism to explain a perplexing phenomenon that has intrigued cardiologists as a result of decades of cardiac stem cell trials,' Dr Jonathan Epstein at the University of Pennsylvania's Perelman School of Medicine in Philadelphia told The Scientist.

Stem cell therapies to repair damaged heart tissue are currently being tested in human clinical trials. In these treatments, human stem cells are injected into the heart and this leads to an improvement in heart function. However, how this works is not fully understood.

One possibility is that the injected stem cells are incorporated into the heart tissue and repair the damage. However, the latest study, published in the journal Nature, suggests that this may not be the case. Instead, the study indicated that the repair is actually a result of triggering the innate immune response.

Researchers injected different types of stem cell or a chemical inducer (zymosan) of the innate immune response into an experimental mouse model of heart disease. They saw improvement in heart function that was similar in all cases, and showed that this repair occurs via activation of macrophage cells of the innate immune system.

'The innate immune response acutely altered cellular activity around the injured area of the heart so that it healed with a more optimised scar and improved contractile properties,' said Dr Jeffery Molkentin at the University of Cincinnati and Cincinnati Children's Hospital Medical Centre, Ohio, who led the study. 'The implications of our study are very straightforward and present important new evidence about an unsettled debate in the field of cardiovascular medicine.'

The work could open up new possibilities for optimising the treatments currently in development, as well as alternative new therapies.

'If there is a chemical off-the-shelf, it would be a much more feasible therapy [than stem cell transplants],'Dr Kory Lavine at Washington University in St Louis, Missouri, told Nature News.

Continue reading here:
Stem cells may trigger immune repair to mend hearts - BioNews

VANCOUVER, British Columbia, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Novoheart (Novoheart or the Company) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the worlds first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.1

Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide in 2017, with an increasing trend in prevalence2. The annual global economic burden of HF is estimated at over US$100 billion3. Accounting for approximately 50% of HF cases, HFpEF in particular is a major and growing public health problem worldwide, with its pathological mechanisms and diverse etiology poorly understood. Due to these complexities, models of the disease available to date, including various animal models, have limited ability to mimic the clinical presentation of HFpEF4. Therefore, drug developers lack an effective tool for preclinical testing of drug candidates for efficacy, and as a result, clinical outcomes for HFpEF have not improved over the last decades, with no effective therapies available.

In collaboration with the Cardiovascular, Renal and Metabolism therapy area of AstraZeneca, the initial phase of the project aims to establish a new in vitro model, leveraging Novohearts proprietary 3-D human ventricular cardiac organoid chamber (hvCOC) technology, that reproduces key phenotypic characteristics of HFpEF. Also known as human heart-in-a-jar, the hvCOC is the only human engineered heart tissue available on the market to date that enables clinically informative assessment of human cardiac pump performance including ejection fraction and developed pressure. Unlike animal models, engineered hvCOCs can be fabricated with specific cellular and matrix compositions, and patient-specific human induced pluripotent stem cells (iPSCs), that allow control over their physical and mechanical properties to mimic those observed in HFpEF patient hearts. Together with Novohearts proprietary hardware and software, this aims to provide a unique assay for understanding the mechanisms of HFpEF, identification of new therapeutic targets, and assessment of novel therapeutics for treating HFpEF patients. Novoheart will exclusively own the intellectual property rights to the newly developed HFpEF hvCOC model.

We are delighted to partner with AstraZeneca, an organization which has long invested in cardiovascular research and is committed to bringing new therapeutic solutions to patients with heart failure, said Novoheart CSO, Dr. Kevin Costa. We look forward to co-developing this new HFpEF hvCOC model into a powerful new tool in the worldwide battle against heart failure.

Regina Fritsche Danielson, Senior Vice President, Head of Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, said, There are significant unmet treatment needs in patients with heart failure with preserved ejection fraction. By combining Novohearts proprietary hvCOC model with our expertise in heart failure, we aim to create the first in vitro model reproducing phenotypic characteristics of heart failure with preserved ejection fraction. This could bridge the gap between in vivo animal models and clinical trials to help accelerate the drug discovery process by providing human-specific preclinical data.

1 Heart Fail Clin. 2014; 10(3):377388.2 Lancet. 2018; 392:1789-1858.3 Int J Cardiol. 2014; 171(3):368-76.4 JACC Basic Transl Sci. 2017; 2(6):770-789.

About Novoheart:

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novohearts bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing of the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients. With the recent acquisition of Xellera Therapeutics Limited for manufacturing Good Manufacturing Product (GMP)-grade clinical materials, Novoheart is now developing gene- and cell-based therapies as well as next-generation therapeutics for cardiac repair or regeneration.

For further information, please contact:Ronald Li, CEOinfo@novoheart.com

For media enquiries or interviews, please contact:Media Relationsmedia@novoheart.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in under the heading Risk Factors in Novohearts annual information form for the year ended June 30, 2019 or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Read the original here:
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca - GlobeNewswire

This report studies the Global Canine Stem Cell Therapy market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Canine Stem Cell Therapy market by companies, region, type and end-use industry.

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

Avail a Sample Copy before Purchase:

https://www.marketinsightsreports.com/reports/07111356900/global-canine-stem-cell-therapy-market-size-status-and-forecast-2019-2025/inquiry?Mode=21

The prominent players in the global Canine Stem Cell Therapy market are:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

Canine Stem Cell TherapyMarket segment by Types:

Allogeneic Stem CellsAutologous Stem cells

Canine Stem Cell TherapyMarket segment by Applications:Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes Top of Form

Global Canine Stem Cell Therapy Market Segmentation by Region:

North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America

Scope of the Report

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

The report is designed to incorporate both qualitative and quantitative aspects of the Canine Stem Cell Therapy Market with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as major drivers & restraining factorswhich will define the future growth of the market.

Get Exclusive Discount at:

https://www.marketinsightsreports.com/reports/07111356900/global-canine-stem-cell-therapy-market-size-status-and-forecast-2019-2025/discount?Mode=21

-Identify the current and future prospects of the global Canine Stem Cell Therapy market in the developed and emerging markets

-Analyse various perspectives of the market with the help of Porters five forces analysis

-Information about the growth of the various material, type, and application that are expected to dominate the market

-Regional and country analysis of the market

-Identify the latest developments, market shares, and strategies employed by the major market players

-3 months analyst support, along with the Market Estimate sheet (in Excel)

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyses key emerging trends and their impact on present and future development.

The research includes historic data from 2013 to 2018, and forecast to 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Contact Us:

Phone: + 1704 266 3234

Mob: +91-750-707-8687

sales@marketinsightsreports.com

irfan@marketinsightsreports.com

See the rest here:
Canine Stem Cell Therapy Market In Depth Research and Overview 2019 to 2025 - The Chicago Sentinel

Autologous Stem Cell and Non-Stem Cell Based Therapies Market covers the latest developments and growth opportunities. Trends, revenue analysis, Global industry share and dynamics are presented to optimize the business. The vital Track insights, opportunities in existing and emerging segments are explained. This report has published stating that the Global Market is anticipated to expand significantly at Million US$ in 2019 and is projected to reach Million US$ by 2023, at a CAGR of during the forecast period.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1146196

In this report we cover the players as far as item fulfillment and business procedure they embrace to continue in Autologous Stem Cell and Non-Stem Cell Based Therapies market. This report analyses the aggressive scene regarding markets, applications, and geologies. The Competitive Strategic Window enables the seller to characterize an arrangement or fit between their capacities and open doors for future development prospects. During a forecast period, it characterizes the ideal or good fit for the merchants to embrace progressive merger and acquisitions procedures, topography extension, inquire about and advancement, new product acquaintance techniques with execute further business development.

The major players profiled in this report include:,U.S. STEM CELL, INC.,Brainstorm Cell Therapeutics,Cytori,Dendreon Corporation,Fibrocell,Lion Biotechnologies,Caladrius Biosciences,Opexa Therapeutics,Orgenesis,Regenexx,Genzyme,Antria,Regeneus,Mesoblast,Pluristem Therapeutics Inc,Tigenix,Med cell Europe,Holostem,Miltenyi Biotec,

With tables and figures helping analyse worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. .

No. of Pages:139

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1146196

Furthermore, the report provides a detailed analysis of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market with analysis of market size by value and volume. Along with this, an analysis of penetration rate and the average revenue generated per user (ARPU) in the market has also been done. The report also includes a detailed analysis of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market by countries, comprising of its market by value, volume, and ARPU and penetration rate.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autologous Stem Cell and Non-Stem Cell Based Therapies for each application, including-Neurodegenerative DisordersAutoimmune Diseases Cancer and TumorsCardiovascular Diseases

Market Share In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Autologous Stem Cell and Non-Stem Cell Based Therapies Report by Material, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Why To Select This Report:

Complete analysis on market dynamics, market status, and competitive Autologous Stem Cell and Non-Stem Cell Based Therapies view is offered.

Forecast Autologous Stem Cell and Non-Stem Cell Based Therapies Industry trends will present the market drivers, constraints and growth opportunities.

This research report will help to understand how the market will grow in the coming years lets say next 5-6 years and so on.

All vital Autologous Stem Cell and Non-Stem Cell Based Therapies Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

This in-depth market study will help to analyze the and take informed decision in their respective field.

Order a copy of Report @https://www.orianresearch.com/checkout/1146196

Key Points Table of Contents

Chapter 1 Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Overview

Chapter 2 Autologous Stem Cell and Non-Stem Cell Based Therapies Up and Down Stream Industry Analysis

Chapter 3 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 4 2014-2019 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 5 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 6 Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 7 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 8 2014-2019 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 9 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 10 North American Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 11 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

Chapter 12 2014-2019 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 13 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Key Manufacturers Analysis

Chapter 14 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 15 Autologous Stem Cell and Non-Stem Cell Based Therapies Marketing Channels Development Proposals Analysis

Chapter 16 Development Environmental Analysis

Chapter 17 Autologous Stem Cell and Non-Stem Cell Based Therapies New Project Investment Feasibility Analysis

Chapter 18 2014-2019 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Productions Supply Sales Demand Market Status and Forecast

Chapter 19 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Development Trend

Chapter 20 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Research Conclusions

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on The World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email:[emailprotected]

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Development, Top Trends and Future Scope with New Industry Opportunities - VaporBlash

Outcome means a special Thanksgiving

Hailie and Treylin Hyman saw the bruising on their baby girls leg as a sign that the active 1-year-old was learning to walk.

But as a blood test would later reveal, little Maci was actually suffering from an extremely rare blood cancer that threatened her life without a risky treatment - atreatmentalmost as dangerous as the disease.

In the beginning, it was very scary, Hailie Hyman told The Greenville News.

I couldnt think of anything but the bad things, she confessed. It was all about the statistics. And the statistics arent good.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

Terrifying months followed the diagnosis, punctuated by one critical complication after another, leaving the Boiling Springs couple to wonder if Maci would survive.

Somehow, though, the blue-eyed toddler pulled through.And now her family is looking forward to a special Thanksgiving with much to be grateful for.

The Hymans journey began last February atMacis 1-year-old well-child checkup.

We had no idea anything was wrong, her mom said.But they did a routine (blood test) and a couple of hours later, we got a call saying her platelets were very low.

The Hymans were referred to a hematologist who found other abnormalities in Macis blood and scheduled a bone marrow biopsy to investigate further.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

During the procedure, the child suffered an aneurysm in an artery and went into cardiac arrest. The team performed CPR on her for 20 minutes before she was stabilized, her mom said.

Later, in the pediatric intensive care unit, she suffered internal bleeding, too.

It was really hard, she said. There were many nights that I would just pray and pray and pray.

Initially believing Maci had leukemia, doctors subsequently determined she had myelodysplastic syndrome, or MDS.

The condition occurs when abnormal cells in the bone marrow leave the patient unable to make enough blood, according to the American Cancer Society.

Its rare, afflicting as few 10,000 Americans a year, though the actual number is unknown.

Maci Hyman, 1, interacts with hospital staff before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

In children, its rarer still. Most people arediagnosed in their 70s.

We were told that just four out of 1 million children get it every year, Hailie Hyman said.

That made the diagnosis elusive at first, said Dr. Nichole Bryant, a pediatric hematologist-oncologist with Prisma Health-Upstate, formerly Greenville Health System.

Shes the only one Ive seen in my career, she said.

Maci had to have regular blood transfusions, antibiotics and other medications to fight the MDS, Bryant said. But the only hope for a cure was a stem cell transplant at the Medical University of South Carolina in Charleston.

When they said that was the only treatment plan for MDS, I of course went to Google, Hailie Hyman said. I read about transplant patients and ...all the complications. It was terrifying. But no matter how many bad things I saw, we had to do it. There is no other option.

The transplantis extremely risky.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

First, high doses of chemotherapy are given to destroy the diseased bone marrow, leaving the patient without an immune system, so fighting infections becomes a challenge. Then healthy donor marrow is infused.

Its also fraught with potentially life-threatening complications, including graft vs. host disease, which occurs when immune cells from the donor attack the patients body, Bryant said. Other complications include permanent kidney damage and gastrointestinal problems.

They have to go to hell and back, she said. But its the only option for long-term survival.

Maci had a really rough start, suffering lots and lots and lots of complications, Bryant said.

Her kidneys failed, so she wound up on dialysis. When she couldnt breathe on her own, she was put on a ventilator. And because she couldnt eat, she had to be tube fed.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

She had blistering sores in her mouth and throughout her GI tract, her mom said. Because her liver wasnt functioning properly, her abdomen filled up with fluid that had to be drained. She was bleeding so profusely in her lungs that one of them collapsed.

Maci, who was sedated through much of it, was put on full life support, she said.

That night we almost lost her, her mom said. We were in the hallway crying our eyes out. We didnt know what do to or think. It was pretty scary for a while.

Somehow, Maci made it.

There were so many times during her first months that it seemed like she would not survive, Bryant said. So the fact that she is here ... is really a miracle.

Macis family found an unrelated donor through the National Marrow Donor Program, enlisting hundreds of other people to join the registry in the process, Bryant said.

Nichole Bryant, M.D.(Photo: Provided)

It was an important part of their journey that maybe didnt directly benefit Maci, she said. But if everybody did that, we wouldnt have difficulty finding a donor for anybody.

Doctors have no explanation for why Maci got MDS. She didnt carry the genetic mutation for it and there is no family history.

She is a rare child - and not in a good way, her mom said, adding,Youve got to laugh sometimes or youre going to cry.

Maci was admitted to MUSC on June 2 and released on Oct. 14.

The Hymans, both 22, spent the entire time in Charlestonwhile Hailies mom cared for their older daughter, Athena, now 2.

Treylins employer held his welding job open for him. And other friends and family members did what they could to help.

We had many, many people very generously donate to us to cover expenses at home and living expenses where we were, Hailie Hyman said.

We are thankful for everyone who helped us through it the cards, the gifts, the donations. Every single cent is greatly appreciated.

They still need to travel to Charleston once a week to see the transplant doctor. In between, Maci is seen in Greenville.

She's doing well, but recovery from a transplant can take months to years, Bryant said.

NEWS CHECKUP

Get more news about developments in health andpatient care at the local, state and national level. Pleaseconsider becominga subscriber. Here's our special offer.

Her kidneys are functioning again so she was able to come off dialysis. But she still must take many medications, including anti-rejection drugs that suppress her immune system and leaveher at risk for infection. And she still must be tube fed.

She is miles ahead of where she was two months ago, Bryant said. But she still has a long way to go. Its a long, long road.

Macis mom says she can be up and playing one day and flopped over on the couch another. She still experiences a lot of nausea and vomiting, but is doing well compared to where she was.

Hailie Hyman pulls her daughter Maci, 1, in a wagon in the hallway before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

So as the nation pauses to give thanks this Thanksgiving, she says the family will be countingtheir many blessings family andfriends, Gods mercy, andthe doctors and nurses who saved Macis life.

She has battled a lot and overcome a lot, she said. I have no doubt she will be able to get through.

Want to know more about becoming a marrow donor? Go to bethematch.org.

Read or Share this story: https://www.greenvilleonline.com/story/news/health/2019/11/27/upstate-sc-toddler-survives-rare-cancer-and-risky-procedure-treat/4158606002/

Continued here:
Upstate SC toddler survives rare cancer and the risky procedure used to treat it - Greenville News

Collagen seems to be one of the buzziest words in wellness, with just about anyone's ears perked up at the mention of the wordno matter how young they are. Because when it comes to healthy skin aging, we know that prevention is everything, and delaying the process before it starts is key to maintaining a smooth, even complexion well into the autumn of life.

Enter all the collagen-promoting creams, serums, supplements, and diets the world has to offerand now, a new drug may be just the trick.

A new study published in the journal GeroScience found a new, unexpected formula to help with healthy aging. This specific drugcalled rapamycinhas been primarily used for patients who have undergone an organ transplant, as it helps prevent the immune system from rejecting the new organ. Rapamycin has also been used to combat a rare lung disease called lymphangioleiomyomatosis, as well as inhibiting tumor growth.

Read this article:
Study Finds This Medication May Reduce Wrinkles & Even Skin Tone - mindbodygreen.com

When it comes to our beauty and skincare products, it's easy for years to pass without an updateor even an upgrade. But because advances in beauty technology are happening at the speed of light, its always important to pause and reassesswhat we're usingfrom dog shampoo to stem-cell skincare. SoI've rounded up the best of the latest trends that have earned a place inmymakeup bag.

Its no secret that Ima major fan of Kjaer Weisthere is something utterly fresh and clean about everything for the face and body, and its as organic as it can get. Enter the latest additions to the line: the cleanser ($95) and toner ($85, both pictured above). Not only does the soft, gel-like cleanser effectively remove all makeup, but its also calming. Follow it with a quick spritz of the toner and you have hydrated and re-balanced skin. Plus, the scents aredreamy.If I could accurately describe them, I would. But I was in Bluemercury downtown recently they have sample bottles to give it a go yourself.Bluemercury, 1500 Main Street, Sarasota. (941) 365-0020

Two things on my must-do-better list: Sunscreen and preventing this neck from aging. Addressing the first, Alastin Skincares HydraTint Pro Mineral Sunscreen SPF 36 ($55) is a revelation. Not only is it lightweight, with broad-spectrum UVA/UVB sun protection, it also protects against environmental pollution and it has a universal tint that enhances most skin tones. Its the first thing Iput on in the morning before taking the dogs for a walk; I love the just-right tinted coverage.

Second, that neck thing. As much as I prefer organic and natural skincarewhen possible, I tend to lean on science for combatting aging. Enter: Nectifirm Advanced ($133). Its next-gen technology based on the ecosystem of the skins microbiome, plus eight peptides that helps skin appear firmer and lifted while lessening the appearance of lines and wrinkles. Not to mention that those in the know at Sarasota Facial Aesthetics rave about the results. Get both products atSarasota Facial Aesthetics,1806 South Osprey Avenue,(941) 955-8384.

I was of the mind that a razor is a razoris a razor. Well, thats changed since theFlamingo razor($9.99) came on my radar. The team raised the bar on shaving after spending years talking to women (what a concept!) who shared the nuances of their personal care rituals and how typical razors fell short. Use this once and it will be clear that they did not overlook those edges of our bodies that need extra attention.Target, 101 N. Cattlemen Road, (941) 360-7520

Speaking of: here's another kind of sunscreen, this time for the eye area. Who knew? I recently discovered Colorescience Total Eye3-in-1 Renewal Therapy SPF 35 ($74)they say it visibly improves the appearance of dark circles, puffiness, fine lines and wrinkles, while protecting the delicate eye area against photoaging with 100 percent SPF 35 mineral sunscreen. I say its great coverage, and if it comes with all of those benefits then...yay!L. Spa, 556 Pineapple Ave., (941) 906-1358

Brace yourself (and maybe your credit card) because Augustinus Baders The Cream ($265) is right there at the cutting edge for stem cell skincare. Get this: the stem cells found in skin lie dormant, awaiting an activation signal to repair the damage inflicted by life and environmental factors.The patented technology TFC8Bader's proprietary "Trigger Factor Complex"is comprised of natural amino acids, high-grade vitamins and synthesized molecules that are found naturally in the skin. Its a repairing force in an ultra-lightweight cream that guides key nutrients and powerful natural ingredients to the skin cells, creating an optimal environment for the body's innate processes of repair and renewal.Thats a lot, but all I know is that I can see the results after a lotta life has happened to my skin. Its crazy good, and I guess for the price it should be. Saks Fifth Avenue, 120 University Town Center Drive, Sarasota. (941) 364-5300

Lastly, this one is for the love of our fur kids, especially those with sensitive skin. The Malin + Goetz Dog Shampoo ($28) is infused with natural botanical amino acids to gently cleanse fur and skin without drying, stripping or irritating. And I can attest that fur dries soft and oh-so-shiny. Malin + Goetz, malinandgoetz.com

Read this article:
Seven Products Our Beauty Editor Used to the Last Drop - Sarasota

Soon youll be able to cover your imperfect flesh with more flesh. (Photo: KaoJapan)

FOX NEWS - Soon youll be able to cover your imperfect flesh with more flesh.

Japanese cosmetics company Kao Corporation has developed a custom synthetic spray-on skin to cover unwanted blemishes, moles or other marks on the natural epidermis.

READ MORE ON FOXNEWS.COM

The artificial product, called est, is composed of tiny, liquid fibers. When sprayed, the substance adheres to human skin, transforming into an extremely thin, derma-like material, the Daily Mail reports.

It has a similar elasticity to skin, and its porous, too. Water vapor and air can pass through this second skin to moisten the living dermis beneath. At its edges, est forms an even thinner bond, helping it blend in with natural flesh.

Est is set to hit the market exclusively in Japan beginning Dec 4. and will sell for roughly $532 as a diffuser and potion combination, with diffuser refills priced at $73. A lotion version will sell for $110, and everything will become available online in January, according to Japanese publication the Asahi Shimbun.

Japanese-language advertisements for the product call it Future Skin, which uses Fine Fiber Technology. Kao has plans to expand the line beginning next year and hopes to soon enter the medical market.

Until then, American consumers can check out the SkinGun by RenovaCare, which shoots a liquid mist infused with human stem cells and can help burn victims skin.

CHECK FOR UPDATES ON FOXNEWS.COM

Read this article:
Makeup brand offers spray-on 'skin' to cover up zits and scars - FOX 10 News Phoenix

Were always happy to geek out over a buzzyskin careingredient when we see it making the rounds on product labels. (See: lactic acid, rosehip oil, bakuchiol) So when we started noticing the proliferation of niacinamide, we were surprised to learn that not only has it been around for a while buttheres a decent body of research behind the multipurpose vitamin. Heres what you need to know about niacinamidesbenefits for your skin.

Niacinamide, a form of vitamin B3 also known as nicotinamide, is a water-soluble vitamin that has potent antioxidant activity and reduces inflammation, saysboard-certified dermatologistDavid Lortscher, CEO of Curology.

It would be an exaggeration to call niacinamide a cure-all, but it does have a pretty extensive range when it comes to the conditions it can treat: acne, oil regulation, fine lines and wrinkles, hyperpigmentation, enlarged pores and sun damage. Its especially good at repairing skins moisture barrier (aka its first line of defense) and protecting against environmental stressorsits even been shown to help prevent skin cancer in certain studies.

Niacinamides nourish and calm redness and inflammation,says DendyEngelman, a board-certified dermatologist in New York. She particularly likes niacinamide for dry and sensitive skin: It has similar effects to retinol by strengthening the skin barrier, but itfortifies from the get-go without sensitivity or irritation.Dr. Lortscher also has high praise: Because of its role in repairing the skin barrier, niacinamide is one of the most effective treatments for photoaging [damage caused by UV rays], according to most anti-aging research.

It starts to get technical here, but as Dr. Engelman explains it, Niacinamide helps support the cellsmetabolic system, specifically fibroblasts. We use fibroblasts tomake and repair DNA,which,in turn, activates collagen production. So by using niacinamides to boost fibroblast production, we are supporting collagen production and repairing damaged collagen.

Lots of products contain niacinamideserums, moisturizers, even cleansersand it works well in conjunction with other active ingredients, like retinol. It can be used both morning and night, though as with any goodskin careregimen, you should follow it up with a sunscreen during the day.

Niacinamide should be compatible with most otherskin careproducts and is well tolerated by all skin types,including sensitiveskin, Dr. Lortscher says. For best results, use leave-on products with niacinamide. Its safe to use around the eyes, anditmay improve the appearance of under-eye darkness and wrinkles.

Convinced yet? Check out a few of our favorite products containing the powerhouse ingredient below.

RELATED: We Ask a Derm: What Ingredients Should You Avoid If You Have Oily Skin?

Of course, the uber-popular, wallet-friendly brand is on top of it. This serum is especially helpful for congested, acne-prone skin: The niacinamides anti-inflammatory propertiescalm active breakouts, while its oil-regulating properties (and the addition of zinc, which also keeps oil in check) help keep new ones from forming.

Buy it ($6)

Nia 24 uses a patented form of niacinamide thats designed to absorb better into skin (and therefore work its magic more effectively). This rich cream strengthens the skin barrier with its namesake ingredient, plus hyaluronic acid, licorice root extract, peptides and ceramides.

Buy it ($118)

Give parched, dull skin a quick pick-me-up with a five-star-rated gel sheet mask. Reviewers rave about its glow-inducing, hydrating properties and the fact that its gentle enough for sensitive skin.

Buy it ($3)

Cursed by the ghosts of pimples past? Niacinamide, glycolic acid and NASA-developed plant stem cells (!) work together to combat hyperpigmentation and scarring.

$20 on Amazon

Derms, dry-skinned gals and makeup lovers alike know oil cleansers are a godsend forwashing off the days makeup withoutstripping any precious natural moisture. This cleanser amps up the effects with niacinamides barrier-strengthening effects, plus offers a gentle exfoliation thanks to fruit enzyme.

Buy it ($42)

SkinCeuticals serums are cult faves for a reason, and this 5 percent niacinamide serum is no exception. Its amped up with amino acids, algae extract and peptides to target the effects of environmental stress and promote collagen production.

Buy it ($112)

RELATED: The Best Face Moisturizer for Dry, Sensitive Skin, According to People Who Use Them

See the original post:
Heres How Niacinamide Benefits Your Complexion (and How to Work It into Your Skin Care Routine) - Yahoo Lifestyle

Birds of a feather may flock together, but the feathers of birds differ altogether.

New research from an international team led by USC scientists set out to learn how feathers developed and helped birds spread across the world. Flight feathers, in particular, are masterpieces of propulsion and adaptation, helping penguins swim, eagles soar and hummingbirds hover.

Despite such diversity, the feather shares a common core design: a one-style-fits-all model with option trims for specialized performance. This simplicity and flexibility found in nature holds promise for engineers looking for better ways to build drones, wind turbines, medical implants and other advanced materials.

Those findings, published today in Cell, offer an in-depth look at the form and function of a feather based on a comparative analysis of their physical structure, cellular composition and evolution. The study compares feathers of 21 bird species from around the world.

Weve always wondered how birds can fly in so many different ways, and we found the difference in flight styles is largely due to the characteristics of their flight feathers, said Cheng-Ming Chuong, the studys lead author and a developmental biologist in the Department of Pathology at the Keck School of Medicine of USC. We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

To gain a comprehensive understanding of the flight feather, Chuong formed a multi-disciplinary international team with Wen Tau Juan, a biophysicist at the Integrative Stem Cell Center, China Medical University in Taiwan. The work involved experts in stem cells, molecular biology, anatomy, physics, bioimaging, engineering, materials science, bioinformatics and animal science. The bird species studied include ostrich, sparrow, eagle, chickens, ducks, swallow, owl, penguin, peacock, heron and hummingbird, among others.

They compared feathers using fossils, stem cells and flight performance characteristics. They focused on the feather shaft, or rachis, that supports the feather much like a mast holds a sail, bearing the stress between wind and wing. They also focused on the vane, the lateral branches astride the shaft that give the feather its shape to flap the air. And they examined how evolution shaped the barbs, ridges and hooks that help a feather hold its form and lock with adjacent feathers like Velcro to form a wing. The goal was to understand how a simple filament appendage on dinosaurs transformed into a three-level branched structure with different functions.

We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

Cheng-Ming Chuong

For birds such as ducks, eagles and sparrows that fly in different modes, the scientists noted significant differences in the feather shaft compared to ground-hugging birds. On the rigid exterior, the shaft cortex was thinner and lightweight, while the interior was filled with porous cells resembling bubble wrap, aligned into bands of various orientations and reinforced with ridges that operate like tiny lateral beams. Together, it forms a light, hollow and buoyant structure to enable flight. Cross-sections of feather shafts of different birds show highly specialized shapes and orientations of the inner core and outer cortex.

The flight feather is made of two highly adaptable architectural modules, light and strong materials that can develop into highly adaptable configurations, Chuong said.

The researchers discovered two different molecular mechanisms guiding feather growth. Cortex thickness was governed by bone morphogenetic proteins, which are molecular signals for tissue growth. The porous feather interior, or medulla, relied upon a different mechanism known as transforming growth factor-beta (TGF-b). Both components originate as stem cells in the birds skin.

By contrast, feathers in flightless birds were simpler, consisting of a dense cortex exterior that is more rigid and sturdy with fewer internal struts and cells found in flying birds. The features were especially pronounced for penguins, which use wings as paddles under the water.

As part of the study, the researchers looked at 100 million-year-old feathers, found embedded in amber in Myanmar. These fossils show early feathers lacked one key feature that modern birds have. Specifically, the researchers report that fossil feathers had barb branches and barbules, which form a feather vane by overlapping, but not hooklets. The hooklets, which act like clasps to turn fluffy feathers into a tight flat plane for high-performance flight, evolved later. The scientists also identified WNT2B, another growth factor, as the agent that controls hooklet formation. These also originated from epidermal stem cells.

Taken together, the findings show how feathered dinosaurs and early birds could form a primitive vane by overlapping barbule plates, although that wasnt aerodynamically fit to carry much load. As more complex composite features occurred in the wing, it got heavier, so feather shafts became stronger yet more lightweight, which led to stiffer feathers and sturdy wings that powered flight to carry birds around the world.

Our findings suggest the evolutionary trends of feather shaft and vane are balanced for the best flight performance of an individual bird and become part of the selective basis of speciation, the study said. The principles of functional architectures we studied here may also stimulate bio-inspired designs and fabrication of future composite materials for architectures of different scales, including wind turbines, artificial tissues, flying drones.

Chuong and Juan are co-leaders of the 31-person team, joined by co-authors Randall B. Widelitz, Shuo Wang, Michael Habib, Ting-Xin Jiang, Zhong-Lai Luo and Ping Wu of the Keck School of Medicine of USC; Wei-Ling Chang, Hao Wu, Yung-Chi Lai, Ming Xing Lei, and Shih-Chieh Hung of the China Medical University Hospital in Taiwan; Ming-You Shie, Jui-Ting Hsu, Heng-Li Huang and Yi-Wen Chen of the China Medical University, Taiwan; Chih-Feng Chen, Ping Chi Tang, Hus Chen Cheng, and Yen-Cheng Lin of the National Chung Hsing University in Taiwan; How-Jen Gu, Yu-Kun Chiu, Tse-Yu Lin, Shun-Min Yang, Tsung-Tse Lee, J.C. Tsai and Yeu-Kuang Hwu of the Institute of Physics, Academia Sinica, Taiwan; Cheng-Te Yao of the Endemic Species Research Institute, Taiwan; Shyh-Jou Shieh of the National Cheng Kung University, Taiwan; Ang Li of the University of Texas, Arlington.

Work at USC was supported by the National Institutes of Health (AR 047364, AR 060306) while team members in Taiwan were supported by grants from their own institutes and the Taiwan government.

More stories about: Biology, Research

Read the rest here:
How birds fly: New USC study examines the evolution of flight feathers - USC News

ANI | Updated: Dec 02, 2019 12:06 IST

New Delhi [India], Dec 2 (ANI): Although business conditions in the Indian manufacturing sector improved in November, the upturn remained subdued compared to earlier in the year and the survey history, according to IHS Markit India Manufacturing Purchasing Managers' Index (PMI) released on Monday.Growth rates for new orders and production were modest despite accelerating from October's recent lows while firms shed jobs for the first time in 20 months and continued to reduce input buying.At the same time, there were only slight increases in input costs and output prices halfway through the third quarter of fiscal year 2019-20.The headline seasonally adjusted IHS Markit India Manufacturing PMI rose from 50.6 in October, when it had fallen to a two-year low, to 51.2 in November. The latest reading was below the survey average (53.8) and indicated only a slight improvement in the health of the sector.Consumer goods provided the main impetus to overall growth while the intermediate goods category returned to expansion territory. Conversely, there was a solid deterioration in operating conditions at capital goods makers.Indian manufacturing production increased only moderately in November, albeit at a quicker rate than October's two-year low.Anecdotal evidence suggested that growth was supported by the launch of new products and better demand, though restrained by competitive pressures and unstable market conditions.Total sales increased for the 25th month in a row with growth strengthening from October's recent low. Besides, the upturn was among the weakest over this sequence.Some firms were able to secure new work amid successful marketing and strengthening demand, but others struggled in the face of competitive conditions, a challenging economic scenario and troubles in the automotive sector.Manufacturers were partly helped by external markets as signalled by a further expansion in international sales. The increase in exports was slight, however, and among the weakest over the past year-and-a-half."PMI data continued to show a lack of inflationary pressures in the sector which, combined with slow economic growth, suggests that the Reserve Bank of India will likely extend its accommodative policy stance and further reduce the benchmark interest rate during December," said Principal Economist at IHS Markit Pollyanna de Lima.Subdued sales prevented hiring in November with payroll numbers declining for the first time in 20 months. A number of companies indicated that workloads had been managed by existing staff while others cited the non-replacement of retirees and non-renewal of temporary contracts.Firms also scaled back input purchasing, with the latest decline the fourth in as many months. Subsequently, the current sequence of falling stocks of purchases that started in August was extended to November.Rates of contraction for both input buying and inventories were marginal, said IHS Markit.The IHS Markit India Manufacturing PMI is compiled from responses to questionnaires sent to purchasing managers in a panel of around 400 manufacturers. The panel is stratified by detailed sector and company workforce size, based on contributions to GDP.IHS Markit is a world leader in critical information, analytics, and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics, and solutions to customers in business, finance, and government. (ANI)

Read more from the original source:
Production growth strengthens in November but remains subdued: IHS Markit - ANI News

Saggy, wrinkled faces could soon be a thing of the past as researchers have identified a key mechanism of how skin ages.

A key protein compound which could represent a new anti-ageing intervention has been discovered by scientists.

Two drugs have been created which offer hope that a fountain of youth could be developed in the future.

The drugs work by boosting levels of a certain protein, which is found in high levels in young skin cells, but begins to dwindle over time as we age.

When the levels of this protein drop, skin cells appear older, misshapen and less elastic.

They also appear thinner and become more blotchy and more fragile.

As long as lots of cells are being born deep below the surface of the skin with high levels of the protein, the skin appears youthful.

In a survival of the fittest scenario, these healthier skin cells out-compete the weaker ones, which go on to die.

But over time, fewer strong skin cells are born and the weaker ones take over, creating a wrinkly appearance to the skin.

In addition, stress, such as exposure to toxic chemicals, or sun damage can also reduce levels of the protein, called COL17A1.

But giving hope to anyone who wishes for a more youthful appearance, researchers said they have found a way to boost its levels.

As well as recreating youthful looks, the drugs have potential to help wound healing and even to prevent skin cancer, the researchers suggest.

Emi Nishimura, from Tokyo Medical and Dental School, and colleagues made the discovery in mice and in human skin tissue grown in the laboratory.

The compounds have yet to be tested on living humans.

Writing in the journal Nature, the authors said they discovered two chemical compounds that boosted COL17A1.

The chemicals, Y27632 and apocynin, when applied to the skin, significantly promoted wound repair by boosting the production of skin cells with high levels of COL17A1, the authors wrote.

The discovery points towards directions for facilitating skin regeneration and reducing skin ageing, they said.

Commenting on the discovery, Ganna Bilusova and James DeGregori, both of the University of Colorado, suggest that the discovery may also help prevent tumours forming.

They wrote, the maintenance of fit stem cells through the years in which an individual is likely to reproduce probably also prevents tumour development, because these fit cells compete with (and eliminate) both damaged stem cells and tumour-prone cells.

They added that the work provides evidence that healthy cells in mammals can also efficiently repopulate adult tissues, replacing unfit or damaged cells.

Both chemicals improve wound healing in mouse tail skin, providing a proof-of-principle demonstration of the therapeutic potential of this new class of drug.

The development also points the way to regenerate other organs apart from the skin, Professor Bilusova and Professor DeGregori wrote.

Future studies are needed to determine the mechanisms of cell competition in other tissues, and to identify compounds capable of reversing ageing in other organs.

Wrinkles are creases, folds, or ridges in the skin.

They normally appear as people get older, but they can also develop after spending a long time in water.

The first wrinkles to appear on a persons face tend to occur as a result of facial expressions.

A tendency to laugh, frown or glare in a certain way can amplify creases in particular regions.

Laughter lines and crows feet tend to be formed from smiling and forehead furrows originate from frowning.

Sun damage, smoking, dehydration, some medications, and environmental and genetic factors also affect when and where people will develop wrinkles.

Most wrinkles tend to appear in the parts of the body which receive the most sun exposure, especially the face and neck, the back of the hands, and the arms.

The upper layer of skin has to renew regularly as it is made of dead cells.

As you get older, it takes longer for your epidermis to renew itself and it shows more and more signs of your age.

Go here to see the original:
Scientists create drugs to keep the skin youthful by boosting levels of a crucial protein - Stock Daily Dish

Mucopolysaccharidoses (MPS) are a group of very rare disorders, also known as orphan diseases. They belong to the group of lysosomal storage diseases which are caused by a deficiency of one of the enzymes involved in the degradation of mucopolysaccharides (the acid glycosaminoglycans or GAGs). The enzymes are coded by genes which produce deficient gene products due to gene variants in each of the two gene-alleles.

Children of two carriers as parents have a 25% risk to suffer from MPS. For many families, the birth of the first affected child is a shock and a disaster. The disease is continuously progressing, and life spans are dramatically decreased without therapy. As a result, extensive efforts are put into the cure of these fatal disorders.

Enzymes are relatively small proteins, produced in the endoplasmatic reticulum of each cell. Before reaching the locus of their function, the lysosomes, additional modifications with special sugars are performed in the Golgi apparatus (glycosylation). Via mannose-6-phosphate marker, they connect to the mannose-6-phosphat receptor on the lysosomal membrane and can reach the final locus of their function. In the lysosomes, enzymes degrade the GAG chains into the smallest molecules for recycling or excretion. Any disturbance in this process leads to the accumulation of non-degraded material, which affects many other cell functions such as homeostasis, calcium metabolism, accelerates apoptosis and induces inflammation processes.

As lysosomes are ubiquitous, any disturbance leads to storage in many different tissues and organs. MPSs are a good example for chronic progressive multi-systemic disorders. The best theoretical option for treatment of any patient is to supplement the missing enzyme which could reach any organ via blood flow and get inside the lysosomes continuing the interrupted degradation processes.

The enzymes are ubiquitous and have some tissue specific compositions. Enzymes produced in the different cells and tissues have their own characteristics and are available on site. The production of recombinant enzymes means that the artificial glycosylation is created in a uniform composition for intravenous substitution with the aim to reach the organs with the blood-flow. There is no doubt that the therapeutic efficacy is ideal for many organs, such as liver, spleen, lung, and skin. All these organs have a good blood circulation and some ability to regenerate.

However, after years of treatment with the already available enzymes, it is shown that some organs are poorly supplied with blood and renewal cycles are slow, the ability to regenerate is decreased. Organs such as bones, cartilage, muscles, cornea, heart valves, meninges or the brain do not show the hope-for effect. All MPS types with brain involvement (neuronopathic forms of MPS types I, II and VII) or predominant skeletal dysplasia (MPS types IVA and B) cannot benefit from enzyme-replacement therapy and do not show the desired improvement.

In animal studies, modifications of glycosylation can change the ability to pass into organs not yet sufficiently reached such as cartilage or bones, but tissue-specific features cannot be sufficiently considered in any artificial production of the enzymes.

Avascular cartilage, heart valves and corneas cannot be reached by blood flow. Also, between blood vessels and brain tissue, several specialised cells form the blood-brain-barrier (BBB) to protect the brain from any unwanted substances in the blood. Therefore, new strategies are necessary to improve the therapeutic efficiency and to provide better outcomes for the affected patients. If patients with MPS I are diagnosed at a very young age, the best option is to treat them with haematopoietic stem cell transplantation (HSCT). Migrating stem cells can reach the brain and other organs, and then differentiate into organ-specific cells producing the missing lysosomal enzymes.

A straightforward method to overcome BBB is the direct injection of a recombinant enzyme into the cerebral fluid. This can be by lumbar puncture (intra-thecal) or intra-ventricular injections in the brain ventricles. Effects can be observed, however unfortunately not all challenges can currently be solved. The liquor flow can be reduced by thickened meninges with storage and vertebral deformities, which are typical for the disease. However, the barrier between cerebral fluid and brain tissue has still not been fully studied. The half-life of enzymes is limited, and the procedure has to be repeated regularly. The clinical trials for patients with MPS I, II, IIIA and IIIB could show some reduced or reversed progression of CNS pathology but long-term effects remain unclear.

Another possibility to overcome BBB is to fuse the enzyme proteins with macromolecules which enter the brain through receptor mediated active transport systems. This physiological transport is known for hormones, neurotransmitters and many other proteins (such as transferrin and insulin). They are transported through the BBB directly into the brain via specific receptores, so, the strategy is to fuse the natural proteins with the artificial enzymes needed in the MPS patient. It is important to note that clinical trials could potentially still show some improvement in affected MPS patients.

Another method is to conjugate the therapeutic enzymes with nano-capsules and to then ferry them across BBB via transcytosis or other transport mechanisms directly into brain cells. Pharmacological chaperones have been proven to be effective in other lysosomal storage diseases such as Gaucher or Fabry disease. Chaperones are able to stabilise three-dimensional conformation of misfolded proteins, such as enzymes. This would be the case of genetic variants causing missense mutation and exchange of only one amino acid in the protein chain. The misfolding pathology reduces stability, half-life and effect of the genetically conditioned enzyme, whereas the chaperone can reverse this disadvantage and increase the activity and efficacy of the enzyme. As a result, pharmacological chaperones are a good option for some diseases and could therefore be an option for some MPS patients in the future.

Some genetic variants cause stop-codons and the production of truncated dysfunctional peptides without any enzymatic activity and degradation within the cell. Stop-codon read through therapy aims for the genetic correction on an RNA level, resulting in the production of a sufficiently functioning gene product. It is already used for some specific mutation for patients with Duchenne muscular dystrophy, but it is too early to predict positive results for patients with MPS I.

Another possibility in the future might be the use of GAG-reducing small molecules such as Genistein, Pentosam polysulfate or Rhodamine B. They are able to influence and/or reduce the synthesis of GAGs which cannot be degraded sufficiently by the genetically changed enzymes with reduced function.

To reduce the GAGs as substrate, could be a chance to create a better relation between substrate and the impaired substrate reducing enzyme. As a result, lysosomal storage could therefore be reduced. Substrate reduction therapy is an established therapeutic concept in some of the other lysosomal storage diseases, but the usefulness in MPS disorders still needs to be proven.

The genetic corrections of DNA sequences in patient cells are no longer only future options as they have now become a reality. Gene variants causing missing or impaired functioning gene products could be replaced by correct genetic sequences and genes. This can be made as an ex vivo approach, where stem cells or fibroblast are removed from the patient and are then cultured in vitro, genetically corrected and consecutively re-injected into the patient.

The genetically corrected DNA in the re-transplanted autologous cells is able to produce correct gene products (in terms of MPS, this is the specific enzyme). The amounts of newly produced enzymes might be sufficient to positively influence the disease course of the treated patients.

An in vivo approach utilises viral vectors which invade cells, and even cell nuclei. Such viruses used are adeno-associated-viruses or lenti-viruses. Such manipulated viruses with the corrective genetic material are directly injected into the patient where they are internalised into deficient cells and are then able to produce the missing gene product. In the case of MPS, the aim is to produce enzyme proteins with sufficient concentrations and activity to prevent the storage of GAGs. Furthermore, clinical trials are underway for several MPS types and therefore, might offer a therapeutic opportunity in early life for affected patients. However, larger studies and a longer follow-up is still needed.

To conclude, MPS are rare genetic disorders and for a long time, they were linked with the myth of being untreatable diseases. Although some of the new therapeutic options are still in clinical trials and not routinely used, the present shows that many of the patients can benefit from the yet available options of HSCT and enzyme replacement therapies. These therapies have an undoubted effect for some of the MPS patients, especially if any form of therapy is started early or if the course of the disease does not affect the nervous system.

However, in the future, new therapeutic options will hopefully bring benefits to those that are not sufficiently improved; the decision of the best therapy will be made on the basis of factors such as the genetic defect, the type of MPS, and the age during treatment. This individualised and personalised therapy will improve the success of MPSs therapies.

Susanne Gerit KircherMedical University of Vienna, AustriaCenter of Pathobiochemistry and Geneticssusanne.kircher@meduniwien.ac.atwww.mps-austria.at

Excerpt from:
Mucopolysaccharidoses: future therapies and perspectives - SciTech Europa

Bioidentical Hormone Doctors: How to Choose

There are many bioidentical hormone doctors to choose from, and after the initial questions about how long they have been practicing and their specialties, there still may be a lot of decisions to be made. So how to you choose among all of these bioidentical hormone replacement therapy doctors for the one that is the right fit for you? We want to provide that advice but also to start with the fact that often the best advice about potential bioidentical hormone doctors comes from word of mouth and reputation. Aside from that there are other steps you can take to choose, and we want to help. Please understand that we are a fully independent website and in order to stay completely unbiased we will not recommend any specific doctor or practice.

Lets start with where you want to end up as far as the bioidentical hormone replacement practitioner that is best for you. First, you want someone who has experience, and specifically experience with the type of treatment you need. You also want someone with experience with people your age and gender. So the first question you should ask when you are interviewing potential bioidentical hormone doctors is about their specific experience with people with your presentation. Know how many people theyve treated, and then it may take a few phone calls to be able to compare and contrast.

Once youve narrowed the field to bioidentical hormone doctors who seem to have experience with people like you, you then want to know their success rate. Now of course this is quite tricky since most bioidentical hormone replacement doctors will report a high success rate, so you may want to ask if theyve ever done a customer satisfaction survey. You might also want to see if their practice is covered by any independent review websites on-line. If you can ask a specific question you may be able to get a more concrete answer, such as whether they asked any specific symptom related questions before and after the treatment, and how often the answers were affirmative.

Of course choosing a practitioner can also be a gut level choice, and we do not want to underestimate that factor. The process of BHRT can be long, since even if the practitioner gets things right pretty quickly there is still a chance that you might need additional treatment at some point even if just a booster. Choosing a practitioner who is smart and experienced is important, but you also need to work with someone you feel is approachable, truly hears you, and takes time to understand your symptoms. These qualities may be a little harder to measure, but they are equally important.

With all the advances in social media and communication technology such as websites where you can providefeedback, there is still one method of gathering information and advice about potential medicalpractitioners, bioidenticalor otherwise, and that is word of mouth. It is impossible to know whether ratings sites have been edited or modified or even contributed to by the practitioners themselves, and relying on the comments of people you dont know is suspect anyway. Reputation remains king.

So what if you are the first among you friends and relatives to consider bioidenticalhormone replacement therapy. You can first turn to your PCP or other medical specialists youve seen, as well as friends of your family who are in the medical field to see if they have names of bioidenticalpractitioners. If you come up empty it may be time to interview a few practitioners, and here is what you want to do:

These are just a few steps you can take to check out your prospective bioidenticalhormone replacement doctor, but again, its best if you hear good things from unbiased and randomly chosen people who have seen him or her like your own friends, colleagues and family.

Here are some websites that might help:

Of course the first thing you should ask are questions about your potential doctors background with BHRT. Bioidentical hormone doctors range from having been in the field of BHRT for many years, and being relatively new to the field. The way you digest the answer to this question may not be as simple as it seems. Experience is of course good, but make sure that any bioidentical hormones therapy doctors you choose who have been doing this for a while have also kept up with the very latest techniques and improvements in the field.

You should also ask how much of your practitioners practice is dedicated to BHRT. There are some who do BHRT full-time, while other make it only a fraction of their practice. While you may not necessarily need a practitioner who does it full-time, you do want someone who makes it a large part of their practice. Also, while it may be okay to have some of the procedures performed by a nurse or other trained practitioner, you should make sure that there is a doctor actively involved in following your case and that you will get to meet with her or him regularly. If the physician will not be regularly involved with administration, ask how easy it will be to contact him or her should you have a question or concern, and again how involved she or he will be in reviewing your progress.

Please feel free to use our comments section to relate your own experience in choosing among bioidentical hormone doctors.

Read more:
Finding the Best Bioidentical Hormone Doctors in 2020

If youre considering hormone replacement therapy (HRT), youll want a highly qualified doctor to help you make the decision. What types of doctors prescribe HRT and how do you find the best one for you? Here are important factors to keep in mind.

The following doctors prescribe hormone replacement therapy (HRT) for menopause:

Any of these types of doctors can help you through menopause. Your job is to find the one who best meets your needs. Here are five steps to finding the best doctor to help you manage your menopause symptoms.

Find a doctor who:

Start by creating a list of potential doctors. Ask your family, friends, and other healthcare providers for recommendations. If youre starting without any referrals, or youre looking for more options, search for doctors on Healthgrades.com.

Healthgrades.com shows patient satisfaction ratings, which give you insight into how your own experience might be with the doctor. Patients rate the doctor and the doctors medical practice, and say if they would recommend the doctor to family and friends.

Take time to research the doctors credentials and experience. Look for a doctor who is board certified and cares for women in menopause on a regular basis. The more experience a doctor has treating your condition, the better prepared he or she is to advise you on the best type of hormone replacement based on your individual circumstances.

Also, confirm that the doctor is in good standing with state and federal agencies and that he or she has no history of malpractice claims or disciplinary actions.

Youll find all this information on Healthgrades.com.

As you narrow down your list of doctors, call each office and ask for a consult appointment to meet and interview the doctor.

Here are some questions to ask the doctor:

Your insurance coverage is a practical matter. To receive the most insurance benefits and pay the least out-of-pocket for your care, you need to choose a doctor that participates in your plan.

But keep in mind, just because a doctor participates in your insurance plan doesnt mean he or she is a high-quality doctor. You still need to consider the doctors experience and expertise.

Continue reading here:
Types of Doctors Who Prescribe Hormone Replacement Therapy ...

Ilyse Hogue, president of the abortion rights organization NARAL Pro-Choice America, said that independent clinics absolutely needed to be better funded, but that ultimately protecting the clinics depended on bigger changes.

I dont think they will be able to continue to operate at all if you dont shift the culture and politics, she said. The trajectory we are on will outlaw service.

Still, some worry that Planned Parenthood and other national groups have overly prioritized politics and power instead of patients and providers. Though Planned Parenthood is perhaps best known as the nations largest abortion provider, it provides a range of health services across more than 600 centers across the country, including contraception; testing for sexually transmitted infections; and hormone therapy for transgender patients.

The tension between Planned Parenthoods political goals and its mission as a health provider was one of the main reasons Dr. Wen, with a background as a physician, had such a stormy tenure as president.

Pamela Merritt, who co-founded a reproductive rights group called Reproaction in 2015, compared Planned Parenthoods legal priorities to a lobbyist for a commercial enterprise like McDonalds, focused on protecting its own business needs. Activists refer to the organization and its outsize influence, she said, as the big pink elephant in the room.

The movement needs independent providers that provide most abortions to be loud and out front, said Ms. Merritt, who described herself as an unapologetic lefty.

For many of those independent providers, the problem extends well beyond politics.

In Alabama, Ms. Grays biggest challenges are practical. Drug prices for medical abortions are high, she cant find a physician to replace her aging medical director, and an electrician recently refused services because he opposed abortion, she said.

Read more:
How a Divided Left Is Losing the Battle on Abortion - The New York Times

This press release was orginally distributed by ReleaseWire

Salt Lake City, UT -- (ReleaseWire) -- 12/01/2019 -- While Intermittent fasting may sound like another dieting craze, the practice of routinely not eating and drinking for short periods of time has shown again to lead to potentially better health outcomes.

In a new study by researchers at the Intermountain Healthcare Heart Institute in Salt Lake City, researchers have found that cardiac catheterization patients who practiced regular intermittent fasting lived longer than patients who don't. In addition, the study found that patients who practice intermittent fasting are less likely to be diagnosed with heart failure.

"It's another example of how we're finding that regularly fasting can lead to better health outcomes and longer lives," said Benjamin Horne, PhD, principal investigator of the study and director of cardiovascular and genetic epidemiology at the Intermountain Healthcare Heart Institute.

Findings from the study will be presented at the 2019 American Heart Association Scientific Sessions in Philadelphia on Saturday, November 16, 2019.

In the study, researchers asked 2,001 Intermountain patients undergoing cardiac catheterization from 2013 to 2015 a series of lifestyle questions, including whether or not they practiced routine intermittent fasting. Researchers then followed up with those patients 4.5 years later and found that routine fasters had greater survival rate than those who did not.

Because people who fast routinely also are known to engage in other healthy behaviors, the study also evaluated other parameters including demographics, socioeconomic factors, cardiac risk factors, comorbid diagnoses, medications and treatments, and other lifestyle behaviors like smoking and alcohol consumption.

Correcting statistically for these factors, long-term routine fasting remained a strong predictor of better survival and lower risk of heart failure, according to researchers.

The Intermountain Healthcare Heart Institute has the opportunity to closely study intermittent fasting because a large portion of its patients do it regularly: a significant segment of Utah's population belongs the Church of Jesus Christ of Latter-day Saints, whose members typically fast the first Sunday of the month by going without food or drink for two consecutive meals, and thus not eating for the period of about a day.

While the study does not show that fasting is the causal effect for better survival, these real-world outcomes in a large population do suggest that fasting may be having an effect and urge continued study of the behavior.

"While many rapid weight loss fasting diets exist today, the different purposes of fasting in those diets and in this study should not be confused with the act of fasting," said Dr. Horne. "All proposed biological mechanisms of health benefits from fasting arise from effects that occur during the fasting period or are consequences of fasting."

Dr. Horne has previously conducted studies about risk of diabetes and coronary artery disease in patients and found that rates are lower in patients who practice routine intermittent fasting. Those studies were published in 2008 and 2012 and suggested that the decades-long development of those chronic diseases may be ameliorated by long-term routine fasting.

Why long-term intermittent fasting leads to better health outcomes is still largely unknown, though Dr. Horne said it could be a host of factors. Fasting affects a person's levels of hemoglobin, red blood cell count, human growth hormone, and lowers sodium and bicarbonate levels, while also activating ketosis and autophagy all factors that lead to better heart health and specifically reduce risk of heart failure and coronary heart disease.

"With the lower heart failure risk that we found, which is consistent with prior mechanistic studies, this study suggests that routine fasting at a low frequency over two thirds of the lifespan is activating the same biological mechanisms that fasting diets are proposed to rapidly activate," Dr. Horne noted.

Researchers speculate that fasting routinely over a period of years and even decades conditions the body to activate the beneficial mechanisms of fasting after a shorter length of time than usual.

Typically, it takes about 12 hours of fasting for the effects to be activated, but long-term routine fasting may cause that time to be shortened so that each routine faster's daily evening/overnight fasting period between dinner and breakfast produces a small amount of daily benefit, they noted.

Further studies are on-going that will answer this question and other questions related to possible mechanisms of effects on development of chronic disease and survival. Additional research will also examine potential psychological effects of fasting and potential effects on appetite and perception of hunger.

Fasting is not for everyone. Researchers caution that pregnant and lactating women should not fast, as well as young children and frail older adults. People who have received an organ transplant, who have a suppressed immune system, who are experiencing acute or severe chronic infections, and those with eating disorders should also not fast.

Also, people diagnosed with chronic diseases especially those who take medications for diabetes, blood pressure, or heart disease should not fast unless under the close care and supervision of a physician because of the severe adverse effects that medications in combination with fasting can cause, including as hypoglycemia.

Other members of the Intermountain research team include: Ciera Bartholomew (BYU), Jeffrey L. Anderson, Heidi T. May, Kirk U. Knowlton, Tami L. Bair, Viet T. Le, Bruce W. Bailey (BYU), and Joseph B. Muhlestein.

This research study was funded by the Intermountain Research and Medical Foundation.

About Intermountain HealthcareIntermountain Healthcare is a not-for-profit system of 24 hospitals, 215 clinics, a Medical Group with 2,500 employed physicians and advanced practice clinicians, a health insurance company called SelectHealth, and other health services in Idaho, Utah, and Nevada. Intermountain is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes and sustainable costs. For more information, please see intermountainhealthcare.org.

For more information on this press release visit: http://www.releasewire.com/press-releases/intermountain-healthcare-study-shows-intermittent-fasting-increases-longevity-in-cardiac-catheterization-patients-1266497.htm

View post:
Intermountain Healthcare Study Shows Intermittent Fasting Increases Longevity in Cardiac Catheterization Patients - Press Release - Digital Journal

Dublin, Nov. 27, 2019 (GLOBE NEWSWIRE) -- The "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo (2019), Zolgensma (2019), Collategene (2019), LUXTURNA (2017), YESCARTA (2017), Kymriah (2017), INVOSSA (2017), Zalmoxis (2016), Strimvelis (2016), Imlygic (2015), Neovasculagen (2011), Rexin-G (2007), Oncorine (2005) and Gendicine (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing.

Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes.

Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.

Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others), location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services).

Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 7 features detailed profiles of the US-based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus-based vectors, Sendai virus-based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development/manufacturing of some of these novel vectors.

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers/acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement/contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents.

Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors/plasmid DNA. It features discussions on different pricing models/approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 14 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 15 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and geographies (North America, EU, Asia-Pacific and the rest of the world).

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech).

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Key Topics Covered

1. Preface2. Executive Summary3. Introduction4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Competitive Landscape5. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Competitive Landscape6. Vector and Gene Therapy Manufacturers (Non-Industry Players): Competitive Landscape7. Vector and Gene Therapy Manufacturers in North America8. Vector and Gene Therapy Manufacturers in Europe9. Vector and Gene Therapy Manufacturers in Asia-Pacific10. Emerging Vectors11. Recent Collaborations and Partnerships12. Key Insights13. Viral Vector and Plasmid DNA Cost Price Analysis14. Capacity Analysis15. Demand Analysis16. Market Sizing and Opportunity Analysis17. Key Drivers and Challenges18. Survey Analysis19. Concluding Remarks20. Executive Insights21. Appendix I: Tabulated Data22. Appendix II: List of Companies and Organizations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4m9jtt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Worldwide Markets for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing, Forecast to 2030 - Robust Pipeline of Therapy Candidates and...